Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial

DiscussionThis is the first trial to evaluate this treatment combination by establishing the maximum tolerated dose and evaluating the efficacy of the combination treatment. M-PHP has shown to be a safe and effective treatment for UM patients with liver metastases and became the standard treatment option in our center. The combination of ICI with M-PHP is investigated in the currently described trial which might lead to a better treatment response both in and outside the liver.Trial RegistrationThis trial was registered in the US National Library of Medicine with identifierNCT04283890. Registered as per February 2020 - Retrospectively registered.EudraCT registration number: 2018-004248-49.Local MREC registration number: NL60508.058.19.
Source: Trials - Category: Research Source Type: clinical trials